Senior Lecturer of Addiction at Edith Cowan University and co-founder of PRISM. Principal Investigator on an Australian MDMA-for-PTSD clinical trial and lead therapist on a psilocybin trial for treatment-resistant depression. Among the first Australians to complete MAPS MDMA-assisted psychotherapy training.
Dr Stephen Bright is a clinically-trained psychologist with more than 20 years in the field. He has been the chief principal investigator of multisite clinical trials and has published research on psychedelics, microdosing, psychometrics, and drug policy. Currently, Stephen is principal investigator on a trial investigating MDMA for PTSD and an associate investigator of a trial of psilocybin-assisted psychotherapy for treatment-resistant depression, for which he is also the lead therapist. He supervises PhD and Masters students' research at Edith Cowan University, where he teaches counselling skills and psychopharmacology.
Psychedelic therapy & harm reduction
Full list: Google Scholar profile | ORCID